PortfoliosLab logoPortfoliosLab logo
AQST vs. ACMR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AQST vs. ACMR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aquestive Therapeutics, Inc. (AQST) and ACM Research, Inc. (ACMR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AQST achieves a -35.45% return, which is significantly lower than ACMR's 138.15% return.


AQST

1D
-0.95%
1M
0.97%
YTD
-35.45%
6M
-32.85%
1Y
25.98%
3Y*
22.65%
5Y*
-0.29%
10Y*

ACMR

1D
2.45%
1M
45.10%
YTD
138.15%
6M
141.95%
1Y
265.21%
3Y*
104.60%
5Y*
25.99%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

AQST vs. ACMR - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
AQST
Aquestive Therapeutics, Inc.
-35.45%81.46%76.24%123.92%-76.81%-27.29%-8.08%-7.62%-58.14%
ACMR
ACM Research, Inc.
138.15%161.26%-22.72%153.44%-72.87%4.95%340.38%69.58%-20.12%

Correlation

The correlation between AQST and ACMR is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.21

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Jul 25, 2018

0.22

Fundamentals

Market Cap

AQST:

$511.28M

ACMR:

$6.55B

EPS

AQST:

-$0.61

ACMR:

$1.33

PS Ratio

AQST:

9.42

ACMR:

6.71

Total Revenue (TTM)

AQST:

$50.27M

ACMR:

$960.23M

Gross Profit (TTM)

AQST:

$20.92M

ACMR:

$424.76M

EBITDA (TTM)

AQST:

-$53.08M

ACMR:

$162.91M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AQST vs. ACMR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AQST
AQST Risk / Return Rank: 5656
Overall Rank
AQST Sharpe Ratio Rank: 5454
Sharpe Ratio Rank
AQST Sortino Ratio Rank: 5959
Sortino Ratio Rank
AQST Omega Ratio Rank: 6262
Omega Ratio Rank
AQST Calmar Ratio Rank: 5353
Calmar Ratio Rank
AQST Martin Ratio Rank: 5252
Martin Ratio Rank

ACMR
ACMR Risk / Return Rank: 9494
Overall Rank
ACMR Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
ACMR Sortino Ratio Rank: 9191
Sortino Ratio Rank
ACMR Omega Ratio Rank: 9292
Omega Ratio Rank
ACMR Calmar Ratio Rank: 9494
Calmar Ratio Rank
ACMR Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AQST vs. ACMR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aquestive Therapeutics, Inc. (AQST) and ACM Research, Inc. (ACMR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AQSTACMRDifference
Sharpe ratioReturn per unit of total volatility

-3.13

Sortino ratioReturn per unit of downside risk

-2.07

Omega ratioGain probability vs. loss probability

1.16

1.45

-0.29

Calmar ratioReturn relative to maximum drawdown

0.43

5.76

-5.33

Martin ratioReturn relative to average drawdown

0.81

14.73

-13.91

AQST vs. ACMR - Sharpe Ratio Comparison

The current AQST Sharpe Ratio is 0.31, which is lower than the ACMR Sharpe Ratio of 3.44. The chart below compares the historical Sharpe Ratios of AQST and ACMR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AQST vs. ACMR - Drawdown Comparison

The maximum AQST drawdown since its inception was -96.68%, which is greater than ACMR's maximum drawdown of -87.23%. Use the drawdown chart below to compare losses from any high point for AQST and ACMR.


Loading charts...

Drawdown Indicators


AQSTACMRDifference

Max Drawdown

Largest peak-to-trough decline

-96.68%

-87.23%

-9.45%

Max Drawdown (1Y)

Largest decline over 1 year

-60.61%

-46.34%

-14.27%

Max Drawdown (3Y)

Largest decline over 3 years

-63.55%

-58.42%

-5.13%

Max Drawdown (5Y)

Largest decline over 5 years

-90.11%

-84.81%

-5.30%

Current Drawdown

Current decline from peak

-78.01%

0.00%

-78.01%

Average Drawdown

Average peak-to-trough decline

-76.92%

-39.55%

-37.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

32.01%

18.11%

+13.90%

Volatility

AQST vs. ACMR - Volatility Comparison

The current volatility for Aquestive Therapeutics, Inc. (AQST) is 21.51%, while ACM Research, Inc. (ACMR) has a volatility of 33.26%. This indicates that AQST experiences smaller price fluctuations and is considered to be less risky than ACMR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AQSTACMRDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.51%

33.26%

-11.75%

Volatility (6M)

Calculated over the trailing 6-month period

68.41%

59.35%

+9.06%

Volatility (1Y)

Calculated over the trailing 1-year period

85.07%

77.68%

+7.39%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

82.62%

80.77%

+1.85%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

87.69%

83.99%

+3.70%

Dividends

AQST vs. ACMR - Dividend Comparison

Neither AQST nor ACMR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

AQST vs. ACMR - Financials Comparison

This section allows you to compare key financial metrics between Aquestive Therapeutics, Inc. and ACM Research, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M20222023202420252026
14.45M
231.26M
(AQST) Total Revenue
(ACMR) Total Revenue
Values in USD except per share items

AQST vs. ACMR - Profitability Comparison

The chart below illustrates the profitability comparison between Aquestive Therapeutics, Inc. and ACM Research, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
46.4%
Portfolio components
AQST - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 14.45M. Therefore, the gross margin over that period was 0.0%.

ACMR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACM Research, Inc. reported a gross profit of 107.24M and revenue of 231.26M. Therefore, the gross margin over that period was 46.4%.

AQST - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported an operating income of -4.20M and revenue of 14.45M, resulting in an operating margin of -29.1%.

ACMR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACM Research, Inc. reported an operating income of 36.18M and revenue of 231.26M, resulting in an operating margin of 15.6%.

AQST - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported a net income of -8.06M and revenue of 14.45M, resulting in a net margin of -55.8%.

ACMR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACM Research, Inc. reported a net income of 17.31M and revenue of 231.26M, resulting in a net margin of 7.5%.


Frequently Asked Questions


AQST and ACMR have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ACMR has higher volatility (33.26%) compared to AQST (21.51%). In terms of maximum drawdown, AQST dropped -96.68% vs ACMR's -87.23%.

ACMR currently has the higher Sharpe Ratio (3.44 vs 0.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AQST and ACMR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer